Eli Lilly: Novo Nordisk Was Just A Warm-Up
Eli Lilly is positioning itself as a strong competitor in the obesity and diabetes treatment market. The company is focusing on its drugs Tirzepatide and Retatrutide, which are expected to drive significant sales growth by 2030. Analysts have set a price target of $1,300 for Eli Lilly's stock, indicating confidence in its future performance.
- ▪Eli Lilly's Tirzepatide is leading the company's near-term obesity and diabetes treatment strategy.
- ▪Retatrutide is aimed at targeting Class III obesity, expanding the company's market reach.
- ▪Eli Lilly's projected sales growth by 2030 is expected to be substantial, with a price target of $1,300 set by analysts.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906385-eli-lilly-novo-nordisk-was-just-a-warm-up"},"author":{"@type":"Person","name":"Wavelength…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
